$CDT News

CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

CDT Equity Announces Patent Filing From Sarborg Limited For Its Intellectual Property Covering Novel Solid Forms Of Respiratory Medicine

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

CDT Equity Inc. Announces Reverse Stock Split

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

CDT Equity Partners With QIMA Life Sciences To Develop Several Of The Company's Autoimmune Skin Disease Assets, Including Novel Tapinarof Combinations In Psoriasis And Vitiligo

CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health

Sarborg Shareholder CDT Equity Notes The Company's Successful Application Of Its Patented Signature Intelligence And Quantum Computing Models To Mental Health And Neuropsychiatric Drug Discovery

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

CDT Equity Reports $23M Market Value And No Remaining Nasdaq Deficiencies

CDT Equity (CDT) Shares Fall 21% After Hours: Here's What Happened

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

CDT Equity Appoints James Bligh As CEO

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market

CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion

CDT Equity Enters Securities Purchase Agreement With Sarborg Investors On July 30, 2026; To Buy 4.76% Of Sarborg

CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane

CDT Equity Inc. Announces Reverse Stock Split